Unssuccessful effort to engage debate within the community of the authorized clinical research gatekeepers charged with protecting the safety and welfare of the human subjects of research–i.e., members of institutional review boards (IRBs–REBs in Canada).
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
The lead story in The New York Times on Thanksgiving day (below) acknowledged several facts demonstrating that children are the victims of major medical malpractice:
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Steven Fiorello, former Chief Pharmacist for the State of Pennsylvania, was arraigned on on Tuesday, November 21, 2006, on Felony and Misdemeanor charges related to his accepting money from drug companies whose drugs he put on the state Formulary.
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press.
The New York Times reports: "For big drug companies, the new Medicare prescription benefit is proving to be a financial windfall larger than even the most optimistic Wall Street analysts had predicted."
